+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy of RO7837195 compared to a placebo in adults with moderately to severely active ulcerative colitis who have not responded well to conventional or advanced treatments. This Phase IIb study aims to assess how effective and safe RO7837195 is for these patients. The study is sponsored by Genentech, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants will undergo a screening period lasting up to 5 weeks to determine eligibility. The main treatment includes a 12-week placebo-controlled induction phase, after which all participants receive RO7837195 during a 40-week active treatment extension. RO7837195 is given according to predefined dose regimens, and the study includes multiple experimental groups receiving different doses, as well as a group initially receiving placebo followed by RO7837195. Throughout the study, participants will have regular assessments to measure clinical remission at week 12, clinical response, endoscopic improvement, and safety through monitoring adverse events and blood levels of the drug. The studys total duration includes the screening, treatment phases, and a safety follow-up after the last dose, with outcome measures tracked up to week 65. Researchers will also monitor for the development of antibodies against RO7837195 to further understand treatment effects and safety.

Age: 18Years +All GendersPhase 2
111 locations
O

Actively Recruiting

Researchers are evaluating a new blood test called Guardant Reveal to detect cancer recurrence in people treated for early-stage solid tumors. The study focuses on linking blood test results to clinical outcomes to prove its usefulness in detecting if cancer comes back. This research involves various types of cancers, including bladder, lung, breast, melanoma, gastrointestinal, ovarian, and others. Participants provide blood samples at enrollment and during regular clinical visits for up to 3 years, aligning with their standard follow-up care. The study includes several cancer groups defined by cancer type and stage. The blood samples are collected 3 to 12 weeks after treatment such as surgery or chemotherapy. This observational study monitors patients without altering their usual care. During the study, participants undergo routine follow-ups and provide clinical data and blood samples to help researchers track cancer recurrence. Researchers measure outcomes like time without distant recurrence over 3 years and test accuracy measures including sensitivity, specificity, and predictive values. The study is led by Guardant Health, Inc. and continues through August 2030, aiming to gather long-term data on the tests performance.

Age: 18Years +All Genders
57 locations
N

Actively Recruiting

Researchers are studying patients with metastatic colorectal cancer to identify clinical and biological factors that predict how well fruquintinib works in real-world settings. The study aims to confirm survival and safety results seen in previous trials and to better understand treatment outcomes, especially in older patients aged 70 and above, who have been underrepresented in earlier research. This cohort is designed to optimize treatment pathways by pinpointing patients who may benefit most from fruquintinib. Participants will receive fruquintinib, an oral drug that targets specific blood vessel growth receptors, given as 5 mg daily for 21 days followed by a 7-day break. This cycle repeats until the cancer progresses, unacceptable side effects occur, the patient dies, or the patient chooses to stop treatment. The study includes patients treated under compassionate use or after marketing authorization in France, integrating routine clinical practice data. During the study, participants will be monitored for overall survival up to one year after starting treatment, which is the main outcome measured. Additional monitoring includes progression-free survival within the same timeframe. The study involves collecting biological samples like circulating tumor DNA and tumor tissue blocks. Safety, survival, and treatment response data will be gathered to support understanding of fruquintinibs effects in everyday clinical use. The study is expected to continue until the end of 2031.

Age: 18Years +All GendersPhase Not Applicable
83 locations